N/A
N=26
Effects of Octacosanol During Taekwondo Training
Oxidative Stress · Dyslipidemias
Bottom Line
View on ClinicalTrials.gov: NCT03557476 ↗Enrolled (actual)
26
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Triglycerides — 34.9; 110 mg/dL
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Octacosanol (Dietary_supplement); Placebo (Dietary_supplement)
- Age
- Pediatric, Adult · 17+ yrs
- Sex
- Male
- Sponsor
- Kosin University
- Primary completion
- Mar 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Triglycerides |
34.9; 110 | — |
| PRIMARY Total Cholesterol |
164; 173.5 | — |
| PRIMARY High-density Lipoprotein |
71; 49.2 | — |
| PRIMARY Low-density Lipoprotein |
92.6; 114.9 | — |
| SECONDARY Malondialdehyde |
0.25; 0.93 | — |
| SECONDARY Superoxide Dismutase |
1450; 1010 | — |
| SECONDARY Glutathione Peroxidase |
66.9; 47.1 | — |
Summary
Taekwondo players undergo rapid reductions of body weight prior to their competition in order to gain a size advantage over the opponent. However, these large weight changes with concomitant high intensity exercise training induce poor lipid profiles and high levels of oxidative stress, which can be detrimental to health and sports performance. Therefore, the purpose of this study was to investigate the ability of the nutritional supplement octacosanol to combat the physiological detriments that can occur from these rapid weight changes paired with high intensity exercise training.
Eligibility Criteria
Inclusion Criteria
- at least 3 years of experience in national taekwondo competitions
- abstain from caffeinated drinks, alcohol, and antioxidant supplements during the whole period of the study
Exclusion Criteria
- no history of chronic use of antioxidants, chronic aspirin, and nonsteroidal anti-inflammatory drugs (NSAIDs)
- No cardiovascular, neurological, metabolic or renal diseases
- no musculoskeletal injuries
Data sourced from ClinicalTrials.gov (NCT03557476). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.